国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
13期
1904-1907
,共4页
王淑琴%王建勇%陈永谦%满洁
王淑琴%王建勇%陳永謙%滿潔
왕숙금%왕건용%진영겸%만길
2型糖尿病(T2DM)%胰岛素抵抗%脂联素%内脂素%罗格列酮(Rosiglitazone)
2型糖尿病(T2DM)%胰島素牴抗%脂聯素%內脂素%囉格列酮(Rosiglitazone)
2형당뇨병(T2DM)%이도소저항%지련소%내지소%라격렬동(Rosiglitazone)
Type 2 Diabetes mellitus%Adiponectin%Visfatin%Rosiglitazone
目的 探讨罗格列酮对2型糖尿病(T2DM)患者血清脂联素、内脂素水平的影响.方法 我院初次诊断的T2DM患者共95例,按照随机数字表法随机分为对照组(40例)和治疗组(55例).对照组接受糖尿病知识教育,进行饮食干预和运动疗法,早晚口服二甲双胍缓释片500 mg,治疗过程中不用影响血糖的其他药物.治疗组在对照组的基础之上,加用罗格列酮4 mg/d.两组疗程均为16周.治疗前、后分别测定患者空腹血糖(FBG)、餐后2h血糖(PBG)、糖化血红蛋白(HbA1C)、空腹胰岛素(FINS)、血清脂联素和内脂素,并计算胰岛素抵抗指数(HOMA-IR).结果 T2DM患者血清脂联素水平明显降低[(7.8±3.2) mg/L vs.(3.2±1.3)mg/L],内脂素水平明显升高[(85.6±18.5)μg/Lvs.(127.8±20.1)μg/L](P<0.01).罗格列酮能明显降低T2DM患者FBG、PBG、HbA1C、FINS水平,改善HOMA-IR (P<0.001);与对照组相比,治疗组血清脂联素水平明显增高[(3.2±0.9)mg/L vs.(7.7±2.1)mg/L],内脂素水平明显降低[(125.3±18.8)μg/L vs.(79.3±16.4)μg/L (P<0.01)].T2DM患者血清脂联素与BMI、FPG、HOMA-IR和内脂素呈负相关(P<0.01);内脂素水平与BMI、FPG和HOMA-IR呈正相关(P<0.01).结论 罗格列酮可通过调控脂联素和内脂素水平,改善胰岛素的敏感性,降低胰岛素的抵抗性,达到纠正高胰岛素血症、降低血糖水平的目的,值得临床推广应用.
目的 探討囉格列酮對2型糖尿病(T2DM)患者血清脂聯素、內脂素水平的影響.方法 我院初次診斷的T2DM患者共95例,按照隨機數字錶法隨機分為對照組(40例)和治療組(55例).對照組接受糖尿病知識教育,進行飲食榦預和運動療法,早晚口服二甲雙胍緩釋片500 mg,治療過程中不用影響血糖的其他藥物.治療組在對照組的基礎之上,加用囉格列酮4 mg/d.兩組療程均為16週.治療前、後分彆測定患者空腹血糖(FBG)、餐後2h血糖(PBG)、糖化血紅蛋白(HbA1C)、空腹胰島素(FINS)、血清脂聯素和內脂素,併計算胰島素牴抗指數(HOMA-IR).結果 T2DM患者血清脂聯素水平明顯降低[(7.8±3.2) mg/L vs.(3.2±1.3)mg/L],內脂素水平明顯升高[(85.6±18.5)μg/Lvs.(127.8±20.1)μg/L](P<0.01).囉格列酮能明顯降低T2DM患者FBG、PBG、HbA1C、FINS水平,改善HOMA-IR (P<0.001);與對照組相比,治療組血清脂聯素水平明顯增高[(3.2±0.9)mg/L vs.(7.7±2.1)mg/L],內脂素水平明顯降低[(125.3±18.8)μg/L vs.(79.3±16.4)μg/L (P<0.01)].T2DM患者血清脂聯素與BMI、FPG、HOMA-IR和內脂素呈負相關(P<0.01);內脂素水平與BMI、FPG和HOMA-IR呈正相關(P<0.01).結論 囉格列酮可通過調控脂聯素和內脂素水平,改善胰島素的敏感性,降低胰島素的牴抗性,達到糾正高胰島素血癥、降低血糖水平的目的,值得臨床推廣應用.
목적 탐토라격렬동대2형당뇨병(T2DM)환자혈청지련소、내지소수평적영향.방법 아원초차진단적T2DM환자공95례,안조수궤수자표법수궤분위대조조(40례)화치료조(55례).대조조접수당뇨병지식교육,진행음식간예화운동요법,조만구복이갑쌍고완석편500 mg,치료과정중불용영향혈당적기타약물.치료조재대조조적기출지상,가용라격렬동4 mg/d.량조료정균위16주.치료전、후분별측정환자공복혈당(FBG)、찬후2h혈당(PBG)、당화혈홍단백(HbA1C)、공복이도소(FINS)、혈청지련소화내지소,병계산이도소저항지수(HOMA-IR).결과 T2DM환자혈청지련소수평명현강저[(7.8±3.2) mg/L vs.(3.2±1.3)mg/L],내지소수평명현승고[(85.6±18.5)μg/Lvs.(127.8±20.1)μg/L](P<0.01).라격렬동능명현강저T2DM환자FBG、PBG、HbA1C、FINS수평,개선HOMA-IR (P<0.001);여대조조상비,치료조혈청지련소수평명현증고[(3.2±0.9)mg/L vs.(7.7±2.1)mg/L],내지소수평명현강저[(125.3±18.8)μg/L vs.(79.3±16.4)μg/L (P<0.01)].T2DM환자혈청지련소여BMI、FPG、HOMA-IR화내지소정부상관(P<0.01);내지소수평여BMI、FPG화HOMA-IR정정상관(P<0.01).결론 라격렬동가통과조공지련소화내지소수평,개선이도소적민감성,강저이도소적저항성,체도규정고이도소혈증、강저혈당수평적목적,치득림상추엄응용.
Objective To explore the effects of rogridone on serum levels of adiponectin and visfatin in patients with type 2 diabetes mellitus (T2DM).Methods 95 patients with initial diagnosis of T2DM were randomly divided into two groups.The control group (40 patients) received education on diabetes,dietary intervention,exercise therapy,and oral mefformin sustained release tablets of 500 mg in the morning and at night separately with no other glycemia-effecting drugs,while the study group received rogridone of 4 mg daily in addition to the therapies used in the control group for 16 weeks.FBG,PBG,HbA1C,FINS,serum adiponectin and visfatin,and HOMA-IR were measured.Results Serum adiponectin level decreased sharply and level of visfatin increased significantly in patients with T2DM [(7.8 ± 3.2vs.3.2 ± 1.3) mg/L and (85.6 ± 18.5 vs.127.8 ± 20.1)μg/L,P<0.01].Rogridone reduced levels of FBG,PBG,HbA1C,and FINS and improved HOMA-IR in the patients (P<0.001).Serum adiponectin level markedly decreased and visfatin level obviously increased in the study group,as compared with the control group [(3.2 ± 0.9 vs.7.7 ± 2.1)mg/L and (125.3 ± 18.8 vs.79.3 ± 16.4) μ g/L,P<0.01].Serum adponectin was negatively correlated with BMI,FPG,HOMA-IR,and visfatin (P<0.01); visfatin level was positively related with BMI,FPG,and HOMA-IR (P<0.01).Conclusions Rogridone can improve susceptibility of insulin and reduce insulin resistance to correct hyperinsulinemia and lower levels of blood sugar by regulating the changes in levels of serum adiponectin and visfatin.It is worth popularizing clinically.